Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab plus radical surgery for stage IIb-IIIA non-small cell lung cancer
ChiCTR1800019861Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Safety and Pathological remission rate. Started Dec 2018; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019861.